Top Markets
Coin of the day
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc.

ODTC
Rank in Stocks #18159
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and... Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
Share Price
$150,000
Last synced: 2025-02-11
Market Cap
$210.38M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Odonate Therapeutics, Inc. (ODTC)

Category

P/B ratio for Odonate Therapeutics, Inc. (ODTC)
P/B ratio as of 2026 TTM: 0
According to Odonate Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Odonate Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH